Critical Contrast: BioMarin Pharmaceutical (BMRN) and Argos Therapeutics (ARGS)
BioMarin Pharmaceutical (NASDAQ: BMRN) and Argos Therapeutics (NASDAQ:ARGS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitabiliy, analyst recommendations, risk, institutional ownership and valuation.
This is a breakdown of recent recommendations and price targets for BioMarin Pharmaceutical and Argos Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioMarin Pharmaceutical currently has a consensus target price of $112.28, suggesting a potential upside of 36.99%. Argos Therapeutics has a consensus target price of $4.13, suggesting a potential upside of 1,681.61%. Given Argos Therapeutics’ higher possible upside, analysts clearly believe Argos Therapeutics is more favorable than BioMarin Pharmaceutical.
Insider & Institutional Ownership
96.8% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 40.4% of Argos Therapeutics shares are owned by institutional investors. 2.5% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
BioMarin Pharmaceutical has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.
This table compares BioMarin Pharmaceutical and Argos Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares BioMarin Pharmaceutical and Argos Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|BioMarin Pharmaceutical||$1.20 billion||11.97||-$106.70 million||($1.09)||-75.19|
|Argos Therapeutics||$904,298.00||10.61||-$48.81 million||($1.75)||-0.13|
Argos Therapeutics has higher revenue, but lower earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioMarin Pharmaceutical beats Argos Therapeutics on 10 of the 13 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
About Argos Therapeutics
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.